A new client came to Facet Life Sciences with a problem. For years, their CRO had advised them they needed additional Phase 3 clinical trials. The Facet team reviewed the data and saw a better way. Facet determined that the existing data was already sufficient to support an NDA submission. They reframed the regulatory strategy, engaged with the FDA, and secured agreement to move forward. The result: savings of millions of dollars and two to three years of development time — for a single client, in a single engagement… and a new product to patients! It wasn't luck. It's what they do. It is the Facet model in action. They take nothing as a given, are creative, and find the best path to FDA approval. Better by Design: Purpose-Built for Emerging Biotech Companies Emerging biotech companies, operating with limited capital and compressed timelines, must identify the most efficient path to approval. Aggressive regulatory strategy, clinical study design and evidence planning are key to achieving value-building milestones. Facet was built with one need in mind: the emerging biotech company operating with limited resources and compressed timelines. They have one "shot on goal" and need it to be right 100% of the time. Purpose-built for small biotech companies, Facet intentionally recruits senior-level professionals with deep, domain-specific expertise — scientists who have run these programs before, met with the FDA, and know how to build a compelling story. Facet’s clients get a team who can apply a breadth of experiences directly to their program. .

Drug development is evolving—shifting from small-molecule drugs (under 500 molecular weight) to larger (above 1,000), more complex compounds—designed to interact with biological pathways more precisely. Therapeutics like peptides and GLP-1 receptor agonists offer enhanced efficacy and target specificity but bring formulation challenges due to their size, fragility and poor oral bioavailability. These complexities demand advanced delivery systems and specialized handling. As a vertically integrated contract development and manufacturing organization (CDMO), Laviana Pharma navigates this complexity. By emphasizing early-stage formulation testing, Laviana helps uncover potential stability and delivery issues early, reducing downstream risks and accelerating the path to clinical success. Its scientific rigor and integrated capabilities make it a vital partner for companies bringing next-generation therapeutics to market. Speed and proximity have become Laviana’s key advantages. It has a specialized formulation laboratory in the U.S. designed specifically for the early-phase development of high-molecular-weight drug candidates. Working locally with U.S. clients means faster decisions, real-time adjustments and shorter timelines. Over the past 20 years, Laviana has helped develop hundreds of candidates and contributed to the successful launch of more than 30 drugs. Some of its early-stage collaborations have led to biotech breakthroughs later acquired by major pharmaceutical firms, an indicator of Laviana’s quiet but critical role in drug development success stories. Starting as a small CRO, Laviana quickly moved on to establishing its own pilot plant. After the R&D and manufacturing sites moved to their new locations, the upgrades Laviana received provided an advantage in equipment and capacity. Not only is Laviana able to do hydrogenation up to 2000 L, but the new trending high potency capability has also been recently added to Laviana’s portfolio. With a manufacturing capacity of up to 6300L and a team of more than 100 scientists, Laviana serves some of the most reputable pharmaceutical companies in the world. “Our role is to make drug development faster,” says Wenting Chen, co-founder and CEO. “Having early-stage development capabilities close to home with our hybrid supply chain strategy proves vital during emergencies like the pandemic when global supply chains get severely disrupted.” This strategy balances the reliability of local collaboration with the efficiency of global infrastructure. Along with the U.S.-based formulation lab, Laviana brings the globally distributed R&D and manufacturing network to advance programs from early development through commercialization. In Cangzhou, China, Laviana manages GMP manufacturing and the scale-up of high-potency APIs, where attention to regulatory compliance and technical detail is non-negotiable. Across the country in Beijing, the process development team uses AI-assisted retrosynthesis not as a buzzword, but as a practical tool, reworking complex synthesis routes to improve yields and cut down production time. Laviana’s fully automated facility in China is at the core of this integration, designed to support projects from early-stage research to late-phase clinical trials and commercial readiness..

In a field where precision, reliability, and trust define outcomes, SeqMatic has emerged as a standout in the next-generation sequencing (NGS) and omics services landscape. Life Sciences Review Magazine has selected SeqMatic as the “NGS Omics Sequencing Services Company of the Year.” The recognition comes from a survey of the magazine’s readership of more than 200,000 professionals, which asked about their experiences with NGS omics sequencing providers. The key evaluation criteria included: • Scientific knowledge and technical expertise • Quality and consistency of the data delivered • Sympathy and comprehension of customer challenges • Communication and transparency during the project lifecycle • Turnaround time • Overall value for money Many scientists noted their frustration when sending carefully prepared samples to a service provider, only to receive subpar results caused by misaligned priorities or insufficient expertise. Selecting the wrong provider can be both costly and time-consuming, with consequences that may derail the progress of a critical project or even affect the direction of an entire company. It is precisely this gap that defines SeqMatic's operating philosophy. How does direct scientist engagement improve accountability and communication in sequencing workflows? While most sequencing service providers rely on a traditional sales model in which customers interact mainly with sales representatives, SeqMatic adopts a distinctly different approach. Its customers engage directly with the scientists processing their samples. Whether the project demands a tight deadline, rare specimens, or an unconventional non-model organism, SeqMatic customers know exactly who is accountable for their project. .

What operational challenges emerge when life sciences companies transition from research into business growth? Scientific innovation slows not in discovery, but in execution, when early-stage companies must build financial and operational structure to function as businesses. Founders, typically grounded in science, enter this phase without systems to manage funding, compliance and team expansion at scale. What follows is a shift in focus, where payroll, reporting, hiring and regulatory demands consume time that should remain on development. Murdock Martell works within that phase, building and managing financial, accounting and HR operational structures that allow companies to function as businesses while they focus on science. How does Murdock Martell adapt operational support as life sciences companies continue scaling operations? Its role extends beyond a standard outsourced CFO model. Here, capabilities are not pre-packaged; they expand in response to recurring client pressure points as companies scale, whether in funding strategy, HR infrastructure or operational support. Engagements extend over multiple years, allowing support to evolve alongside the business rather than through point-in-time interventions. “We’ve grown the practice by just listening to the client,” says Claire Martell, co-founder, CEO and president. “As companies grow, they start needing support in different areas, and we expand based on where those needs show up.” That responsiveness becomes most visible in capital strategy. Early-stage companies rely on grant funding, providing non-dilutive capital but introducing increasing reporting and compliance requirements as they scale. The firm helps clients determine when funding accelerates progress and operational burden outweighs its value. Support is therefore continuously customized. Budget, growth pace and internal capability define how responsibilities are distributed, making each engagement adaptable. Supporting Growth, Transitions and Outcomes Why is phased financial transition important as internal teams develop within growing organizations today? As companies grow and begin forming internal teams, the structure once dependent on external support shifts inward. Murdock Martell adjusts as internal capability develops, building the financial and operational foundation early, then transferring ownership as in-house teams take shape. The relationship moves into a fractional CFO model, where oversight remains while execution shifts internally. This progression allows the firm to remain involved throughout a company’s lifecycle, from early-stage formation through scaling, exit or transition..

What challenges arise when scientific and technical functions operate separately in clinical research? There are numerous factors which contribute to success in life sciences research. Two key factors depend on how effective scientific rigor and advanced technology come together to support clinical development. Within pharmaceutical, biotechnology, and research, departments typically operate at one end of the spectrum, specializing in their function. Pratico Consulting bridges these functions by combining clinical trial knowledge and technical expertise to drive execution and deliver impactful outcomes downstream. The company brings over 30 years of proven expertise in data standards, clinical & statistical programming, statistical computing environment application development, publishing, submissions, and cross-functional leadership. These capabilities reflect an intimate understanding of how clinical data flows through the development lifecycle, ensuring alignment, quality, and continuity in functions. “Our difference is not just in analyzing data, but in understanding how it moves, evolves, and used across its lifecycle,” says Gregory Purnsley, Managing Principal..

What are the core inefficiencies in traditional biotech procurement, and how do they impact scientific execution? Biotech and pharmaceutical procurement remain fragmented to this day. Highly trained scientists spend hours navigating disconnected supplier ecosystems, as procurement processes remain optimized for finance rather than the pace of scientific work. This creates a significant innovation bottleneck. Sourcing alone takes over six hours per lab manager per week, while vendor onboarding can stretch between two and four weeks. ZAGENO empowers scientists and procurement teams with an AI-powered, seamless execution layer embedded directly into the scientific workflow. Its Single Entry Point model brings suppliers, purchasing, data and compliance together within an AI-powered lab supply procurement platform, turning procurement from a downstream administrative task into a continuous part of experimental planning and execution. ZAGENO serves as infrastructure for modern scientific organizations, embedding procurement directly into the execution loop of science. “Procurement should never slow down science. By removing complexity and embedding intelligence into the workflow, we accelerate innovation itself,” says Florian Wegener, CEO..